001     305582
005     20251101115631.0
024 7 _ |a 10.1016/j.meddos.2025.09.006
|2 doi
024 7 _ |a pmid:41168045
|2 pmid
024 7 _ |a 0958-3947
|2 ISSN
024 7 _ |a 1873-4022
|2 ISSN
037 _ _ |a DKFZ-2025-02241
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Duma, Marciana Nona
|b 0
245 _ _ |a Regional nodal irradiation in breast cancer patients: A treatment planning study of the breast cancer working group of the German society of radiation oncology.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761918062_171917
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a The aim of the study was to analyze the interinstitutional differences in the planning process/approach of regional nodal irradiation (RNI) in breast cancer patients in expert centres. Based on a predefined risk constellation, the left breast and the axillary, periclavicular and internal mammarian lymph node areas had to be irradiated. The study focused on left-sided RNI. One CT dataset (free breathing) each of a regular (R) adipose (A) and a slender patient (S) were centrally selected and all target volumes (CTV: level II, III, IV + internal mammary artery chain region-IMC, left breast, PTV and OARs) were contoured according to the ESTRO recommendations. A total dose of 50.4/1.8 Gy was set as the dosage with free choice of technique/inclinic constraints. Dose files were analyzed centrally as DICOM files (CTV: D95%, D50%, D1% and V95%; OAR: D1%, Dmean, V20Gy, V30Gy, V40Gy and the absolute V95% of normal tissue outside the PTV). A total of 18 data sets were analyzed. Differences of almost 10 Gy in TV coverage were significant (p < 0.05). This was evident between patients e.g., for CTV_IMC D95%/D50% S:47.1Gy ± 1.9/50.1Gy ± 0.6; R:39.4Gy ± 8.4/47.6Gy ± 4; A:38.3Gy ± 10.4/47.9Gy ± 4.4) and PTV_IMA D95%/D50% (S:37.6Gy ± 3.9/49.7Gy ± 0.8; R:27.9Gy ± 7.8/46.9Gy ± 3.3; A:25.6Gy ± 9.7/47.5Gy ± 2.8). Patient-related dose differences were also significant for OAR`s: Dmean heart (S:4.6Gy ± 1.1; N:6.1Gy ± 1.2; A:7.9Gy ± 2.1), humeral head (S:8.3Gy ± 2.7; N:3.8Gy ± 0.7; A:6.4Gy ± 1.7), and thyroid (S:17.7Gy ± 2.7; N:14.3Gy ± 1.6; A:27.9Gy ± 4.5). Patient anatomical factors and institutional planning differences create significant dosimetric variations in breast cancer radiation therapy, emphasizing the need for personalized planning approaches that incorporate patient-specific constraints and age-dependent risk considerations.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Lymphatics
|2 Other
650 _ 7 |a RNI
|2 Other
700 1 _ |a Borm, Kai
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Hehr, Thomas
|b 2
700 1 _ |a Piroth, Marc D
|b 3
700 1 _ |a Gerd, Fastner
|b 4
700 1 _ |a Baumann, René
|b 5
700 1 _ |a Combs, Stephanie E
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Corradini, Stefanie
|b 7
700 1 _ |a Dunst, Jürgen
|b 8
700 1 _ |a Krug, David
|b 9
700 1 _ |a Hörner-Rieber, Juliane
|b 10
700 1 _ |a Matuschek, Christiane
|b 11
700 1 _ |a Schmeel, Leonard Christopher
|b 12
700 1 _ |a Fietkau, Rainer
|b 13
700 1 _ |a Strnad, Vratislav
|b 14
700 1 _ |a Budach, Wilfried
|b 15
773 _ _ |a 10.1016/j.meddos.2025.09.006
|g p. S0958394725000561
|0 PERI:(DE-600)2000560-X
|p nn
|t Medical dosimetry
|v nn
|y 2025
|x 0958-3947
909 C O |o oai:inrepo02.dkfz.de:305582
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MED DOSIM : 2022
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-06
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-06
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21